Kiniksa Pharmaceuticals To Present At Goldman Sachs 45Th Annual Global Healthcare Conference


(MENAFN- GlobeNewsWire - Nasdaq) HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & media section of the company's website at . A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
...


MENAFN04062024004107003653ID1108296981


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.